Overview

To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the pharmacokinetics of avanafil in subjects with mild and moderate renal impairment and to assess the safety and toleration of avanafil in subjects with mild and moderate renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
VIVUS, Inc.